icotrokinra
Stories
-
Johnson & Johnson reports ICOTYDE achieves 58% ACR20 response in biologic-naïve psoriatic arthritis
The Phase 3 ICONIC-PsA 1 study met its primary endpoint, with 58% of ICOTYDE-treated patients achieving an ACR20 response versus 41% of placebo at Week 16. Safety data through Week 24 showed no new safety signals and were consistent with the established safety profile of ICOTYDE.